Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum

Subjects will perform 6 (six) visits during the study:

Screening visit, performed 30 to 1 day before the visit 1, when eligible subjects will be recruited and first evaluations will be performed; visit 1, which is the baseline and when the injections will be performed; visit 2, 30 +/- 3 days after the injections, when evaluations will be performed; visit 3, 90 +/- 3 days after the injections, when evaluations will be performed; 4, 120 +/- 3 days after the injections, when evaluations will be performed; visit 5, 150 +/- 3 days after the injections, when evaluations will be performed.

Assessment of percentage (%) of responders, after 5 months of injection, to the effects of two BT-A preparations, Dysport® and Xeomin®, by measuring frontalis m. wrinkle intensity at maximum contraction, as measured by visual Wrinkles Severity Scale (WSS).

Inclusion criteria

• Subject agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol;
• Female subjects;
• Phototype I to IV;
• Subjects aged between 18 and 60 years;
• Subjects naive for BT-A treatment;
• Subjects presenting the same degree of moderate (2) to severe (3) wrinkles on the left and right side of forehead under maximum voluntary contraction of the frontalis m. according WSS;
• Subjects with Minor's test showing at least grade III in the Sweating Intensity Visual Scale;
• Medical history and physical examination which, based on the investigator's opinion, do not prevent the subject from taking part in the study or from making use of the products under investigation;
• Subjects of childbearing age should present a negative urine pregnancy test at baseline and should be using a highly effective contraceptive method during all study;
• Availability of the subject throughout the study (5 months);
• Subject agreeing not to undergo other cosmetic or dermatological procedures during the participation in the study;
• Subjects with sufficient schooling and knowledge to enable them to cooperate to the degree required by the protocol.

Exclusion criteria

• Pregnant women or women intending to become pregnant in the following 5 months after screening;
• Lactation period;
• Subjects participating in other clinical trials;
• Any prior surgery affecting the frontalis and/or orbicularis muscles, prior blepharoplasty or brow lift;
• Any prior cosmetic procedures, including fillers, or scars that may interfere with the study results;
• Subjects with neoplastic, muscular or neurological diseases;
• Subjects taking aminoglycoside and penicillamine antibiotics, quinine or Ca2+ channel blockers;
• Subjects with inflammation or active infection in the area to be injected;
• Subjects presenting evident facial asymmetry;
• Subjects with a history of adverse effects, such as sensitivity to the components of any of the study drug formula, ptosis or any other adverse effect which, in the investigator's opinion, should prevent the subject from participating in the study;
• Subjects presenting Myasthenia Gravis, Eaton-Lambert Syndrome and motor neuron disease;
• Subjects with coagulation disorders or taking anticoagulants;
• Subjects with known systemic autoimmune diseases;
• Subjects with a history of non-adherence to medical treatment or showing unwillingness to adhere to the study protocol;
• Any condition that, in the opinion of the investigator, can compromise the evaluation of the study.